瑞舒伐他汀对癌症患者静脉血栓栓塞风险标志物的影响
这项双盲交叉随机对照试验纳入38例接受全身治疗的晚期癌症患者,随机分配至瑞舒伐他汀20 mg每日一次或安慰剂组,治疗3-4周后交叉,洗脱期3-5周。瑞舒伐他汀未使D-二聚体等血栓前标志物发生统计学显著变化,CRP降低40%(4.3 mg/L,95%CI -11.0至+2.5 mg/L)。作者认为他汀在癌症人群中的血栓预防作用仍不明确。
要点
- 瑞舒伐他汀未使D-二聚体等血栓前生物标志物发生统计学显著变化。
- CRP降低40%,即4.3 mg/L(95%CI -11.0至+2.5 mg/L),与安慰剂相比。
- 在癌症患者中检出循环TF、FIXa和FXIa的比例分别为26%、68%和71%,健康个体中未检出。
核心结论
- 瑞舒伐他汀未使接受化疗的晚期癌症患者的静脉血栓栓塞风险生物标志物出现有利变化。
- 他汀作为癌症人群血栓预防手段的作用仍不确定。
研究设计与样本
- 双盲、交叉、随机对照试验,纳入接受全身治疗的晚期癌症患者。
- 参与者被分配至瑞舒伐他汀20 mg每日一次或安慰剂组,治疗3-4周后交叉至另一治疗,洗脱期3-5周。
- 38例入组参与者中24例(63%)完成研究。
- 在兩個治疗期开始和结束时检测D-二聚体、C反应蛋白(CRP)、可溶性P-选择素(sP-选择素)、凝血因子VIII(FVIII)、凝血酶生成及探索性生物标志物,包括组织因子(TF)、活化凝血因子IX(FIXa)和活化凝血因子XI(FXIa)。
- 主要结局为瑞舒伐他汀与安慰剂相比D-二聚体的变化。
主要发现
- 瑞舒伐他汀未使D-二聚体水平或任何其他生物标志物发生统计学显著变化。
- CRP水平降低40%,即4.3 mg/L(95%置信区间,-11.0至+2.5 mg/L),与安慰剂相比。
- 事后分析中,在第一线治疗期间初始接受瑞舒伐他汀的参与者D-二聚体降低13%。
- 循环TF、FIXa和FXIa在癌症患者中的检出率分别为26%、68%和71%,而健康个体中未检出。
关键数值与推荐
- 瑞舒伐他汀20 mg每日一次,治疗3-4周后交叉,洗脱期3-5周。
- 主要结局为D-二聚体变化,瑞舒伐他汀未引起统计学显著变化。
- CRP降低40%,即4.3 mg/L(95%CI -11.0至+2.5 mg/L)。
- 事后分析中初始接受瑞舒伐他汀者D-二聚体降低13%。
- 循环TF、FIXa、FXIa检出率分别为26%、68%、71%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 38例入组参与者中仅24例(63%)完成研究,原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Essentials Statins lower venous thromboembolism risk in general but have not been studied in cancer patients. We completed a randomized trial of rosuvastatin vs. placebo among cancer patients on chemotherapy. Rosuvastatin did not significantly lower prothrombotic biomarkers including D-dimer. The role of statins in venous thrombosis prevention in cancer patients remains unknown. SUMMARY: Background Statin therapy is associated with lower risk of venous thromboembolism (VTE) but has not been prospectively evaluated in patients with advanced cancer. Objectives We determined if statin administration in this high-risk population reduces the risk of VTE, based on established and emerging biomarkers. Patients/Methods This double-blind, crossover, randomized controlled trial among patients with advanced cancer receiving systemic therapy allocated participants to rosuvastatin 20 mg daily or placebo for 3-4 weeks prior to crossover to the alternative therapy, with a 3-5-week washout. D-dimer, C-reactive protein (CRP), soluble (s)P-selectin, factor VIII (FVIII), thrombin generation and exploratory biomarkers focusing on endogenous thrombin potential, including tissue factor (TF), activated factor IX (FIXa) and activated factor XI (FXIa), were measured at the start and end of both treatment periods. The primary outcome was change in D-dimer with rosuvastatin compared with placebo. Results Of 38 enrolled participants, 24 (63%) completed the study. Rosuvastatin did not cause statistically significant changes in D-dimer levels or any other biomarker. CRP levels decreased by 40%; 4.3 mg L-1 (95% confidence interval, -11.0 to +2.5 mg L-1 ) compared with placebo. In post-hoc analysis, participants who received rosuvastatin initially during their first line of treatment had a 13% decrease in D-dimer. Circulating TF, FIXa and FXIa were detected in 26%, 68% and 71% of cancer patients despite not being found in healthy individuals. Conclusions Rosuvastatin did not cause favorable changes in biomarkers of VTE risk in advanced cancer patients receiving chemotherapy. The role of statin therapy as thromboprophylaxis in the cancer population remains uncertain.
引用
- Ades S, Douce D, Holmes CE, et al. Effect of rosuvastatin on risk markers for venous thromboembolism in cancer. J Thromb Haemost. 2018. PMID: 29575637. doi:10.1111/jth.14004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。